AI Article Synopsis
- - Aromatase inhibitors, especially letrozole (LZ), are now recognized as effective first-line treatments for inducing ovulation and enhancing intrauterine insemination outcomes.
- - LZ is gaining traction as an adjunct to gonadotropin therapy in IVF, particularly beneficial for women with estrogen-sensitive cancers, by lowering estrogen levels.
- - Recent studies suggest that LZ can aid poor responders in IVF, mitigate ovarian hyperstimulation syndrome, and improve the luteal phase, while also being useful for preparing the endometrium in frozen-thawed embryo transfers.
Article Abstract
Aromatase inhibitors, particularly letrozole (LZ), are now established as first-line ovulation induction agents, offering an effective ovarian stimulation strategy to enhance outcomes of intrauterine insemination. In recent years, they have also emerged as potentially valuable adjuvants to gonadotropin ovarian stimulation for in vitro fertilization, particularly in fertility preservation in women with estrogen-responsive cancers. Their primary mechanism of action is to reduce the circulating estrogen levels by inhibiting androgen aromatization. Recent studies have provided evidence that this property may confer therapeutic advantages in other patients undergoing in vitro fertilization. In this study, evidence supporting the role of adjuvant LZ in poor responders, as a moderator of ovarian hyperstimulation syndrome symptoms, and an agent for improving the luteal phase after ovarian stimulation is reviewed. The use of LZ for endometrial preparation in the frozen-thawed embryo transfer cycle is also considered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.fertnstert.2024.10.040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!